Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.
about
Phleboviruses and the Type I Interferon ResponseRNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever virusesRapid Accumulation of Virulent Rift Valley Fever Virus in Mice from an Attenuated Virus Carrying a Single Nucleotide Substitution in the M RNASafety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review StudyRift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse modelCharacterization of the Uukuniemi virus group (Phlebovirus: Bunyaviridae): evidence for seven distinct speciesRecovery of Recombinant Crimean Congo Hemorrhagic Fever Virus Reveals a Function for Non-structural Glycoproteins Cleavage by Furin.Inflammatory Biomarkers Associated with Lethal Rift Valley Fever Encephalitis in the Lewis Rat ModelMapping of transcription termination within the S segment of SFTS phlebovirus facilitated the generation of NSs-deletant viruses.Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeEmerging phlebovirusesEvaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine.Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSsMolecular biology of rift valley Fever virusRift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and preventionDeveloping vaccines against foot-and-mouth disease and some other exotic viral diseases of livestock.Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice.Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infectionProtection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccineTowards a safe, effective vaccine for Rift Valley fever virusDeletion mutants of Schmallenberg virus are avirulent and protect from virus challengeAdvances in Rift Valley fever research: insights for disease preventionThe consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging.Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes.Development of a novel, single-cycle replicable rift valley Fever vaccine.Gouleako virus isolated from West African mosquitoes constitutes a proposed novel genus in the family BunyaviridaeRecombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in miceInhibitors of the interferon response enhance virus replication in vitro.A ΩXaV motif in the Rift Valley fever virus NSs protein is essential for degrading p62, forming nuclear filaments and virulence.Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replicationDevelopment of a novel nonhuman primate model for Rift Valley fever.Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challengeHigh-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection.RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever VirusThe dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever virusesRift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.
P2860
Q26747457-8EA3186A-1C1F-48C9-A229-A5877BF13673Q27487321-02F9EA6C-A024-4815-9F4F-AD29B6308180Q27491320-932B38A3-6094-4E72-94C2-32BAB7DB8F82Q28066283-375A6333-8A29-46E5-8A7C-EC581F50FE22Q28539632-E5CC2CA9-1A68-4055-86DB-40282F7F0B4AQ33405078-CC2C697A-A4CE-4B96-8591-947537B38410Q33422481-348A81EA-293D-4A1F-A63B-E6822FFFF479Q33429285-49872FD8-4E17-4BC5-A7DE-C7EDF055EEBFQ33442499-942D5EE9-9B77-4BBB-98B5-321ECCEEF940Q33570326-A6484F73-8A66-4491-8970-D1121BF1F811Q33617793-669D2B4D-FB39-4EA0-8967-E920145A7A1AQ33621078-5D430B85-885B-47DC-BE2B-67929929F242Q33652514-415C05A3-025A-4FDC-8E93-6BDE0130400CQ33653450-AA4F3447-4CC4-4449-8B75-64B10142DD4CQ33705717-CCFE9B56-C946-4C7F-A9DD-7200FAEB7D3FQ33886954-D88E7046-3AC8-462C-B6ED-3798BE398423Q33960690-9D3FC4A2-06D5-4758-BFD5-10959073B3F7Q34011420-F34FB2A1-F472-489D-AF91-B23517AB8BFCQ34097995-DBEC2E0A-01B2-40B2-B09B-15B29EF02108Q34221766-D2C4E941-397F-4181-A07A-1230C8B02C51Q34260234-E76ED1ED-146F-45DA-B8F7-2520968C00BEQ34431934-552DD6C2-BD73-430F-8DC8-26E678D10C40Q34677989-000F9BE2-288C-40F1-9DE4-FD9E01BC1290Q34991418-80C13AD1-08C0-4492-9417-4379154669FDQ35077969-9CDE9C88-14CA-4678-8416-BB6C88080ECEQ35097103-A20719AF-E9B7-4CDC-9D1E-984058D60B5CQ35097798-DA83A451-4BFD-4BE7-9541-6F0B223482F9Q35126733-53DA1F2D-083A-4E34-9DE5-91BBE4CD873EQ35192825-D9472FD5-3E15-421A-B4D6-790EE73A6C29Q35202797-30D3FB36-04D9-4BC9-B7B9-17A70E3F28A5Q35414495-670EC820-2AC6-45DC-9C5D-BA28618951ECQ35616459-89F1E6FB-9C0D-42B9-917E-366B7348DC1BQ35801885-27869853-B69A-4FF5-BB3F-41B8A07BB64FQ35826546-61F5A599-7B89-4872-96DD-34554A7B2281Q35868079-2FAA72D7-F5AA-4093-AF53-5FDEF7C3682FQ35893112-EA6FFFB8-E4E8-48F2-9527-691680308A85Q36086242-B9BE4FA9-FD2C-4929-BDB7-01D647E7DD7DQ36155392-737E0C25-18D7-4C40-989C-FE70DA01A941Q36650409-D1565384-DEBB-4CB1-8C3E-86F8AC5C26F1Q36827204-69623638-8F37-445C-BDB0-5FB122297879
P2860
Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rift valley fever virus lackin ...... fected and vaccinated animals.
@ast
Rift valley fever virus lackin ...... fected and vaccinated animals.
@en
type
label
Rift valley fever virus lackin ...... fected and vaccinated animals.
@ast
Rift valley fever virus lackin ...... fected and vaccinated animals.
@en
prefLabel
Rift valley fever virus lackin ...... fected and vaccinated animals.
@ast
Rift valley fever virus lackin ...... fected and vaccinated animals.
@en
P2093
P2860
P356
P1433
P1476
Rift valley fever virus lackin ...... fected and vaccinated animals.
@en
P2093
Amy L Hartman
Bobbie Rae Erickson
Brian H Bird
César G Albariño
P2860
P304
P356
10.1128/JVI.02501-07
P407
P577
2008-01-16T00:00:00Z